ESPR Esperion Therapeutics, Inc. gains 15% May 29, 2019

Posted By: Rajesh Srivastava - Wednesday, May 29, 2019

Share

& Comment

Esperion Therapeutics, Inc., a lipid management company, focuses on developing and commercializing oral therapies for the treatment of patients with elevated low-density lipoprotein cholesterol (LDL-C). Its lead product candidate is Bempedoic acid, an inhibitor of ATP-citrate lyase that reduces cholesterol biosynthesis that is in Phase III long-term safety and tolerability study. Esperion Therapeutics, Inc. was founded in 2008 and is headquartered in Ann Arbor, Michigan.http://www.priceseries.com/trade/ESPR-Esperion-Therapeutics-Inc-stock-gains-15-percent-a-Trade-Record-by-priceSeries-2019050320190529.html

About Rajesh Srivastava

Techism is an online Publication that complies Bizarre, Odd, Strange, Out of box facts about the stuff going around in the world which you may find hard to believe and understand. The Main Purpose of this site is to bring reality with a taste of entertainment

0 comments:

Post a Comment

Subscribe to: Post Comments (Atom)

Copyright © priceSeries Daily Results™ is a registered trademark.

Designed by Templateism. Hosted on Blogger Platform.